Medtronic Stock Price, News & Analysis

Medtronic plc (NYSE:MDT) announced significant 12-month results from a multicenter randomized controlled trial, validating DTM™ Spinal Cord Stimulation (SCS) therapy's effectiveness for chronic back pain. At 12 months, 84% of DTM SCS patients reported at least 50% pain relief, versus 51% for conventional SCS (p=0.0005). Notably, 69% of DTM SCS patients experienced profound relief (>80% VAS score reduction) compared to 35.1% with conventional therapy. The study underscores the potential advantages of DTM SCS and its novel approach in pain management.

Medtronic (NYSE: MDT) announced promising results from the IN.PACT BTK Study, a feasibility trial evaluating the IN.PACT 0.014 drug-coated balloon (DCB) for treating critical limb ischemia (CLI) patients with chronic total occlusion. Conducted across nine sites in Europe, the study showed a significant reduction in late lumen loss at nine months for the DCB group compared to the conventional angioplasty group (0.59mm vs. 1.26mm, p=0.017). Safety outcomes were comparable for both groups. The study reflects Medtronic's commitment to advancing treatment for critical vascular conditions.

Medtronic (NYSE:MDT) has partnered with The Foundry to develop a cutting-edge transcatheter mitral valve repair technology, with the resulting company, Half Moon Medical, now ready for an early feasibility study, recently approved by the FDA.

This technology addresses severe mitral regurgitation, affecting about 4 million U.S. patients. The Half Moon device aims to restore valve function and could complement Medtronic's existing Intrepid valve system, enhancing their product portfolio in minimally invasive heart therapies.

Medtronic (NYSE:MDT) announces the SMART trial, a head-to-head study of its Evolut™ TAVR system against Edwards' SAPIEN 3 valves for patients with severe symptomatic aortic stenosis. Enrolling 700 patients, it focuses on small annuli and TAV-in-SAV procedures, representing over 40% of the TAVR market. Additionally, Medtronic plans the Evolut™ EXPAND TAVR I feasibility study for moderate and asymptomatic severe aortic stenosis patients, targeting 150 participants. This aims to address a significant patient group, as over 2 million in the U.S. live with these conditions.

Medtronic recently highlighted its growth strategy during the virtual 2020 Investor Day, aiming for accelerated revenue growth and sustainable double-digit total shareholder returns. CEO Geoff Martha emphasized an industry-leading pipeline of innovative products, including the Micra™ AV pacing system and soft tissue surgical robot. Medtronic targets annual organic revenue growth of over 5% and adjusted earnings per share growth of over 8%. The company also expects to maintain a cash conversion ratio greater than 80%, aiming to return more than 50% of free cash flow to shareholders.

Medtronic has released its FY20 Integrated Performance Report, highlighting significant ESG initiatives. Key achievements include aiming for carbon neutrality by FY30 and achieving 100% gender pay equity in the U.S. The company reported a 36% reduction in greenhouse gas emissions compared to FY13 and set plans to cut emissions by 50% by FY25. The report reflects Medtronic's commitment to social responsibility, especially during COVID-19, where it increased ventilator production and donated $36 million to relief efforts.

Medtronic plc (NYSE:MDT) announced a donation of nearly $1 million in personal protective equipment (PPE) to the International Medical Corps to aid COVID-19 relief efforts in the U.S. and Puerto Rico. The donation includes over 1.1 million surgical masks and 408,000 KN95 respirators, targeting hospitals in COVID-19 hotspots. This support highlights Medtronic's commitment to frontline health workers and underserved communities during the pandemic, as recognized by various officials from both Medtronic and International Medical Corps.

Medtronic plc (NYSE:MDT) has launched the Adaptix™ Interbody System, the first navigated titanium implant featuring Titan nanoLOCK™ Surface Technology. This technology combines various surface textures to enhance strength and promote bone growth. Adaptix, which received FDA approval in August 2020, addresses surgeons' needs for improved spinal fusion outcomes. The system integrates with Medtronic's navigation platforms, facilitating accurate placement during surgery. The announcement was made at the North American Spine Society annual meeting, marking a significant step in Medtronic's commitment to advancing spine care.